Alamar Bio
The Future of Precision Proteomic Analysis
Alamar Biosciences is creating the most sensitive proteomics platform that can profile thousands of proteins simultaneously from as little as one microliter of plasma. Its fully automated, high-throughput precision proteomics platform will pave the way to discovering the deepest secrets of the proteome. It has the potential to fulfill the promise of the human plasma proteome to transform healthcare with a new wave of biomarkers for early detection and prevention of common diseases.
Cognoa
Digital Diagnostics and Therapeutics for Autism
For autistic children, the earlier a diagnosis is made, the more effective the intervention. However, demand for pediatric neurologists is so high that many children wait more than a year to be evaluated.
Cognoa is developing a digital test that leverages machine learning and AI to analyze video of a child in question and return a diagnosis to the parent. They are also developing a digital therapeutic for children on the autistic spectrum.
Cyted
Early Detection of Pre-Cancerous Esophageal Conditions
Esophageal adenocarcinoma (EA) prevalence has increased 6-fold in Western countries over the past 40 years; about half of patients die within a year of diagnosis. Detection of Barret’s esophagus, a pre-cancerous state, greatly increases chances of survival, but the current method is an invasive and expensive endoscopy.
Cyted is developing a simple molecular test for Barret’s that can be administered at home, eliminating the need for hospital-based surveillance that take half a day to administer and misses up to 90% of current sufferers.
Geneoscopy
Colorectal cancer is the second-leading cause of cancer deaths annually in the United States and early detection and treatment are key to improve survival. Geneoscopy is a clinical-stage diagnostics company focused on new methods for early detection of gastrointestinal diseases and cancer. Geneoscopy has developed a proprietary isolation and screening platform to assay RNA biomarkers from stool. This platform is non-invasive and can be used by patients at home.
LumiraDx
A Universal Point-of-Care Diagnostics Platform
Founded by a team of highly experienced diagnostics entrepreneurs, LumiraDx is developing rapid, high-quality point of care diagnostics systems whose performance is comparable to that of central pathology labs.
LumiraDx’ platform is highly scalable, with the ability to manufacture 100m+ test strips a year with their novel print technology.
LumiraDx has recently received emergency use authorization for its Covid-19 test from the FDA, and has signed a collaboration agreement with CVS to roll its test out nationwide.